Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 4/20 | 0.38 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGAV | P06756 | 2/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.36 |
| ▸ | ACE | P12821 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23452178 | 1.00 | ITGB1 (0.38) | ITGB1ITGA5ITGB3ITGAVITGA4 | |
| SCHEMBL23452176 | 1.00 | ITGB1 (0.38) | ITGB1ITGA5ITGB3ITGAVITGA4 | |
| SCHEMBL1747463 | 0.76 | NOTUM (0.33) | MAPTPOLB | |
| SCHEMBL23888590 | 0.76 | NOTUM (0.33) | MAPTPOLB | |
| SCHEMBL21465821 | 0.76 | NOTUM (0.33) | MAPTPOLB | |
| SCHEMBL1854645 | 0.72 | MAPT (0.36) | MAPTPOLB | |
| SCHEMBL2715722 | 0.71 | ACE (0.56) | ITGB1ITGA5ITGB3ITGAVITGA4 | |
| SCHEMBL2805870 | 0.71 | ACE (0.56) | ITGB1ITGA5ITGB3ITGAVITGA4 | |
| SCHEMBL2712732 | 0.71 | ACE (0.56) | ITGB1ITGA5ITGB3ITGAVITGA4 | |
| SCHEMBL1853020 | 0.71 | GAA (0.47) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230049231-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-02-16 | — | — | US | disclosed |
| US-20230040182-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-02-09 | — | — | US | disclosed |
| EP-4041405-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-4041408-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114828963-A | Arylheterobicyclic compounds as Kv1.3 potassium SHAKER channel blockers | D·E·萧尔研究有限责任公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-114728177-A | Aryl heterobicyclic compounds as Kv1.3 potassium Shaker channel blockers | D·E·萧尔研究有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021071803-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071832-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| CN-101151262-B | Substituted piperidines | SPEEDEL EXPERIMENTA AG | 2011-07-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040182-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNB1, KCNJ2, KCNB2 | ITGB1 1851/4885ITGA5 3404/4885ITGB3 1454/4885 |
| US-20230049231-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNB1, KCNJ2, KCNB2 | ITGB1 1851/4885ITGA5 3404/4885ITGB3 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.